A5009005773- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- DNA Repair Mechanisms
- Cancer Genomics and Diagnostics
- 3D Printing in Biomedical Research
- Drug-Induced Ocular Toxicity
- Graphene and Nanomaterials Applications
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Microfluidic and Bio-sensing Technologies
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- Advanced Breast Cancer Therapies
- Cytokine Signaling Pathways and Interactions
- Multiple Myeloma Research and Treatments
- Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Peripheral Neuropathies and Disorders
- Chemokine receptors and signaling
- Immune cells in cancer
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Reproductive Biology and Fertility
- Chemotherapy-related skin toxicity
University of Michigan
2015-2024
U-M Rogel Cancer Center
2022
Michigan Medicine
2018
University of Cagliari
2018
Michigan Center for Translational Pathology
2014-2017
University of Chicago Medical Center
2010-2014
University of Chicago
2010-2011
Cancer Genetics (United States)
2010
National Institutes of Health
2005-2007
National Cancer Institute
2005
Breast cancer cells traffic to and from the peripheral blood within specific vascular niches, this migration can be therapeutically targeted.
Abstract Molecular analysis of circulating tumor cells (CTCs) at single-cell resolution offers great promise for cancer diagnostics and therapeutics from simple liquid biopsy. Recent development massively parallel RNA-sequencing (scRNA-seq) provides a powerful method to resolve the cellular heterogeneity gene expression pathway regulation analysis. However, scarcity CTCs massive contamination blood limit utility currently available technologies. Here, we present Hydro-Seq, scalable...
A highly sensitive microfluidic system to capture circulating tumor cells from whole blood of cancer patients is presented. The device incorporates graphene oxide into a thermoresponsive polymer film serve as the first step an antibody functionalization chemistry. By decreasing temperature, captured may be released for subsequent analysis. As service our authors and readers, this journal provides supporting information supplied by authors. Such materials are peer reviewed re-organized online...
PARP inhibitors have shown promising results in early studies for treatment of breast cancer susceptibility gene (BRCA)-deficient cancers; however, resistance ultimately develops. Furthermore, the benefit (PARPi) triple-negative cancers (TNBC) remains unknown. Recent evidence indicates that TNBCs, cells display "cancer stem cell" properties are resistant to conventional treatments, mediate tumor metastasis, and contribute recurrence. The sensitivity (CSC) PARPi is unknown.We determined CSCs...
Abstract Purpose: Paclitaxel exposure, specifically the maximum concentration (Cmax) and amount of time remains above 0.05 μmol/L (Tc>0.05), has been associated with occurrence paclitaxel-induced peripheral neuropathy. The objective this study was to validate relationship between paclitaxel exposure Experimental Design: Patients breast cancer receiving 80 mg/m2 × 12 weekly doses were enrolled in an observational clinical (NCT02338115). plasma measured at end 16–26 hours after first...
Patients with breast cancer estrogen receptor-positive tumors face a constant risk of disease recurrence for the remainder their lives. Dormant tumor cells residing in tissues such as bone marrow may generate clinically significant metastases many years after initial diagnosis. Previous studies suggest that dormant display "stem-like" properties (cancer stem cell, CSC), which be regulated by immune system. To elucidate role system controlling dormancy and its escape, we studied...
Abstract The enumeration of circulating tumor cells (CTCs) has shown prognostic importance in patients with breast cancer. However, CTCs are highly heterogeneous diverse functional properties, which may also be clinically relevant. To provide a comprehensive landscape the patient's disease, further CTC analysis is required. Here, sensitive and reproducible graphene oxide based assay utilized to isolate characterize from 47 metastatic cancer patients. captured high purity, requiring only few...
PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer genomic alterations known to be drug targets. Results from cohorts metastatic breast (BC) FGFR1 FGFR2 treated sunitinib are reported. METHODS Eligible had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, no standard treatment options....
Aim: First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [Tc >0.05]). Second, screen additional pharmacogenes for associations with Tc >0.05. Methods: Pharmacogene panel genotypes were translated into genetic phenotypes >0.05 (n = 58). Results: Patients predicted low-activity had shorter after adjustment age, body surface area and race (9.65 vs 11.03 hrs, β 5.47, p 0.02). This...
Aims Chemotherapy‐induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation ( EPHA4 , EPHA5 EPHA6 and EPHA8 ) associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold). Methods Germline DNA from 60 patients breast cancer was sequenced. measured using the 8‐item sensory subscale (CIPN8) patient‐reported CIPN20. Associations 3 models were tested incorporating genetics into...
3099 Background: The MCT inhibitor CYT-0851 blocks lactate transport resulting in glycolytic cancer cell death. Monotherapy clinical activity has been previously reported lymphoma and solid tumors. Preclinical studies assessing with chemotherapy identified enhanced growth inhibition when combined 5-FU or gem supporting evaluation. Methods: Patients (pts) tumors were treated + standard dosing of cape 21- 28-day cycles, respectively, following a 3+3 design. primary objective was to determine...
3006 Background: Homologous recombination (HR) is an essential, high-fidelity mechanism to repair DNA double strand breaks (DSBs). Inhibition of HR in cancer cells leads accumulation unrepaired DSBs and tumor cell death. This the first reporting first-in-human study CYT-0851, oral, first-in-class, small molecule inhibitor RAD51-mediated repair. Methods: Patients (pts) with advanced hematologic solid tumors were treated continuous 28-day cycles increasing doses CYT-0851 accelerated titration...
Scalp cooling therapy (SCT) is the most effective method to reduce chemotherapy-induced alopecia (CIA), a highly distressing side effect of cancer treatment. Despite data supporting SCT efficacy and safety, use in United States not widespread. Oncologists' interactions with scalp were examined identify facilitators barriers implementation.A 33-question survey was distributed through ASCO Research Survey Pool nationally representative, random sample 600 oncology providers. Outcome measures...
Abstract Background: Triple negative breast cancers (TNBCs) have a poor prognosis and are therapeutic challenge due to resistance multiple chemotherapy drugs. Growing evidence suggests that cancer stem cells (CSCs) may be promising targets for treating TNBCs. Poly ADP ribose polymerase (PARP) inhibitors shown striking activity in preclinical models of BRCA-deficient carcinomas. However they less efficacious tumors without germline BRCA mutations, which account more than 80% all Our data...
Abstract Genomic instability is recognized as a driver of tumorigenesis and cancer progression. Loss tumor suppressors or activation oncogenes can induce DNA damage stress, promoting genomic creating dependencies upon key repair pathways. The clinical success PARP inhibitors has highlighted the potential targeting these therapeutically to synthetic lethality. We have developed novel RAD51 selectively target cancers that elevated levels and/or reduced repair. critical component homologous...